Company intelligence / Profile preview

INSMC

Bridgewater, New Jersey, United Statesinsmc.ro ↗

Ownership: Private
Development stage: Commercial

Overview

Insmed is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, particularly respiratory conditions. They have a commercial product, Arikayce, for NTM lung infection caused by MAC, and a late-stage pipeline including brensocatib (Phase 3 for non-CF bronchiectasis) and TPIP (Phase 2 for PAH/IPF). Insmed leverages a proprietary liposomal drug delivery technology and emphasizes a patient-first culture, having received multiple workplace awards.

Therapeutic areas: PulmonologyCardiovascularInfectious Diseases
Modalities: Small moleculeLiposomal drug deliveryBiologic
Industry: Biotech

Beyond the preview

Go deeper on INSMC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INSMC.

Explore the full profile